Association between HIV in pregnancy and antiretroviral therapy, including protease inhibitors and low birth weight infants

Infectious Diseases in Obstetrics and Gynecology

Volumn 8, Issue 2, 2000, Pages 94-98

  Goldstein, Phillip J ^a,c   Smit, René ^a   Stevens, Monique ^a   Sever, John L ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Antiretroviral drugs; HIV; Pregnancy; Protease inhibitors (PIs)

Indexed keywords

PROTEINASE INHIBITOR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; ENZYME ACTIVITY; FEMALE; HEALTH SERVICE; HUMAN; INTRAUTERINE INFECTION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MEDICAL RECORD; PREMATURE LABOR; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; VERTICAL TRANSMISSION;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PROGNOSIS; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 0034003457     PISSN: 10647449     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-0997(2000)8:2<94::AID-IDOG6>3.0.CO;2-V     Document Type: Article

References (16)

1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al. Reduction of maternal infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
2. Centers for Disease Control and Prevention. Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV 1 for Maternal Health and for Reducing Perinatal HIV 1 Transmission in the United States. Morb Mortal Wkly Rep 1998;47(RR-2):1-30.
3. Lorenzi P. 12th World AIDS Congress Geneva, Switzerland, 1998. Abstract.
4. Scott, G. PACTG Perinatal Research; ACTG. Pediatrics Newsletter July 23, 1998.
5. Kuhn L, Abrams EJ, Matheson PB, Thomas PA, Lambert G, Bamji M, Greenberg B, Steketee RW, Thea DM. Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS 1997;11:429-435.
6. Macgregor SN. Human immunodeficiency virus infection in pregnancy. Clin Perinat 1991;18:33-50.
7. Johnstone FD, Raab GM, Hamilton BA. The effect of human immunodeficiency virus infection and drug use on birth characteristics. Obstet Gynec 1996;88:321-326.
8. Braddick MR, Kreiss JK, Embree JB, Datta P, Ndinya-Achola JO, Pamba H, Maitha G, Roberts PL, Quinn TC, Holmes KK. Impact of maternal HIV infection on obstetrical and early neonatal outcome. AIDS 1990;4: 1001-1005.
9. Markson LE, Turner BJ, Houchens R, Silverman NS, Cosler L, Takyi BK. Association of Maternal HIV Infection with Low Birth Weight. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:227-234.
10. European Collaborative Study: perinatal findings in children born to HIV infected mothers. Br J Obstet Gynec 1994;101:36-141.
11. Johnstone FD. The Effect of HIV Infection on Pregnancy Outcome. Baillieres Clin Obstet Gynec 1992;6: 69-84.
12. Guyer B, Martin JA, MacDorman MF, Anderson RN, Strobino DM. Annual Summary of Vital Statistics - 1996. Pediatrics 1997;100:905-918.
13. Flexner C. Drug therapy: HIV protease inhibitors: N Engl J Med 1998;338:1281-1292.
14. Abbott Laboratories Norvir (Ritonavir). Physicians Desk Reference 1998.
15. Agouron Pharmaceuticals Viracept (Nelfinavir Mesylate). Physicians Desk Reference 1998.
16. Keirse MJ. Progesterone administration in pregnancy may prevent preterm delivery. Br J Obstet Gynecol 1990:97;149-154.